


Applicant : Wang et al.
 Serial Number : 10/007,342
 Filed : October 22, 2001
 Page : 2

Amendments to the claims:

Claims 1-22 (Previously withdrawn)

23. (Cancelled) A compound of the formula:



wherein

A is selected from the group consisting of: a direct bond, $-\text{SO}_2-$, $-\text{NHSO}_2-$, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{S})-$, $-\text{NR}^5(\text{C}=\text{O})-$, $-\text{O}(\text{C}=\text{O})-$, and $-\text{C}(\text{R}^6\text{R}^7)(\text{C}=\text{O})-$, wherein R_5 , R_6 , and R_7 are independently selected from the group consisting of hydrogen and lower alkyl;

D is selected from the group consisting of: $-\text{SO}_2-$, $-(\text{C}=\text{O})-$, and $-(\text{C}=\text{S})-$;

E is selected from the group consisting of: C_1 – C_{10} hydrocarbon, substituted aryl, heterocyclyl, and substituted heterocyclyl;

X is selected from the group consisting of: $-\text{O}-$, $-\text{S}-$, $-\text{NR}^8-$, and $-\text{N}(\text{R}^8)(\text{C}=\text{O})-$ wherein R^8 is selected from the group consisting of: absent, hydrogen, and lower alkyl;

X is a single bond, or in the alternative, when X is NR^8 wherein R^8 is absent, is a double bond;

R^1 is selected from the group consisting of C_1 – C_{20} alkyl, aryl, alkylaryl, substituted alkylaryl, C_1 – C_{10} alkyloxy, C_3 – C_{10} oxaalkyl, aryloxy, substituted aryl, substituted aryloxy, heterocyclyl, and heterocyclyloxy;

Applicant : Wang et al.
 Serial Number : 10/007,342
 Filed : October 22, 2001
 Page : 3


R^2 is selected from the group consisting of: C_1 – C_{10} hydrocarbon, substituted aryl, and heterocyclyl; and

R^3 and R^4 are independently selected from the group consisting of: C_1 – C_{20} alkyl, C_1 – C_{10} hydrocarbon, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocyclyl, and substituted heterocyclyl; or, in the alternative, R^3 and R^4 taken together with the carbon atoms to which they are attached form a cyclic moiety selected from the group consisting of: aryl and substituted aryl.

24. (Cancelled) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 23, or a pharmaceutically acceptable salt or solvate thereof.

25. (Cancelled) A pharmaceutical composition according to claim 24, further comprising at least one additional antiviral agent.

26. (New) A compound of the formula:






wherein:

R^1 is chosen from the group consisting of C_1 – C_{20} alkyl, aryl, alkylaryl, substituted alkylaryl, C_1 – C_{10} alkoxy, C_1 – C_{10} oxaalkyl, aryloxy, substituted aryl, substituted aryloxy, heterocyclyl and heterocyclyloxy;

R^2 is chosen from the group consisting of C_1 – C_{10} hydrocarbon, substituted aryl and heterocyclyl;

Applicant : Wang et al.
 Serial Number : 10/007,342
 Filed : October 22, 2001
 Page : 4

A is chosen from the group consisting of a direct bond, $-\text{SO}_2-$, NHSO_2- , ,



is thiazolidine;

R^5 , R^6 and R^7 are chosen from the group consisting of hydrogen and lower alkyl;

D is $-\text{SO}_2-$; and

E is chosen from the group consisting of C_1 – C_{10} hydrocarbon, substituted aryl, heterocyclyl and substituted heterocyclyl.

27. (New) A compound according to claim 26 wherein E is chosen from aryl, heteroaryl, substituted aryl and substituted heteroaryl.
28. (New) A method of treating or preventing a proteaseprecipitated disease which comprises administering to a mammal suffering from said disease or at risk to said disease a therapeutically effective amount of a compound according to claim 26.
29. (New) A method according to claim 28 wherein said disease is HIV, AIDS, or a related condition.
30. (New) A method according to claim 28 wherein said disease is malaria.
31. (New) A method according to claim 28 wherein said disease is chosen from connective tissue disease, muscular dystrophy, breast cancer and Alzheimer's disease.
32. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 26, or a pharmaceutically acceptable salt or solvate thereof.
33. (New) A pharmaceutical composition according to claim 32 comprising at least one additional antiviral agent.